SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
Ratios
6 Sheets · From 2023 to 2018Configuration
Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | - - | - - | 99.00 | - - | 69.16 | 92.25 | |
| Profit Margin | - - | - - | -126.41 | - - | -4,460.06 | -5,968.50 | |
| Operating Margin | - - | - - | -132.35 | - - | -4,566.03 | -6,297.28 | |
|
EPS Growth
|
- - | -58.75 | 19.69 | -250.00 | -43.98 | -0.20 | |
| EPS USD | -80.00 | -127.00 | -102.00 | -357.00 | -514.00 | -515.00 | |
| Return on Assets (ROA) | -36.81 | -16.35 | -7.68 | -38.28 | -43.50 | -44.79 | |
| Return on Equity (ROE) | 91.97 | -17.00 | -7.94 | -41.01 | 48.10 | -51.92 | |
| Return on Invested Capital (ROIC) | 99.10 | -17.29 | -8.03 | -40.78 | 49.12 | -50.34 | |
| Solvency | |||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | -0.11 | 0.47 | 0.29 | 0.83 | 0.97 | |
| Debt/Equity | - - | -0.11 | 0.49 | 0.31 | -0.92 | 1.13 | |
| Debt/EBITDA | 247.09 | 554.90 | 313.99 | 59.35 | 22.18 | 49.51 | |
|
Debt/Capitalization
|
- - | -0.11 | 0.49 | 0.30 | -0.93 | 1.11 | |
| Long-Term Debt/Capitalization | - - | - - | 0.24 | 0.03 | -0.84 | 0.95 | |
| Interest Debt per Share USD | - - | -0.01 | 0.06 | 0.03 | 0.08 | 0.11 | |
| Debt Growth | - - | - - | - - | -52.78 | 306.74 | 34.39 | |
| Liquidity | |||||||
| Current Ratio | 1,279.03 | 2,768.26 | 2,915.38 | 1,277.69 | 1,174.87 | 640.80 | |
| Quick Ratio | 1,241.45 | 2,737.28 | 2,887.47 | 1,246.29 | 1,160.09 | 620.61 | |
| Cash Ratio | 1,241.45 | 2,737.28 | 835.26 | 346.90 | 132.21 | 225.22 | |
| Operating Cash Flow Ratio | -300 | -300 | -100 | -400 | -300 | -200 | |
| Turnover | |||||||
| Inventory Turnover | - - | - - | - - | - - | - - | 13.60 | |
| Receivables Turnover | - - | - - | - - | - - | - - | 91.86 | |
| Payables Turnover | - - | 7.23 | 25.85 | 14.29 | 23.67 | 5.71 | |
|
Asset Turnover
|
- - | - - | 6.07 | - - | 0.98 | 0.75 | |
| Fixed Turnover | - - | - - | 1,159.32 | - - | 33.65 | 22.61 | |
| Coverage | |||||||
| Interest Coverage | - - | - - | - - | - - | 36,689.41 | - - | |
| Asset Coverage | - - | - - | 20,400 | 32,800 | 11,000 | 9,000 | |
| Cash Flow Coverage (CFGR) | - - | 13,069.97 | -1,177.43 | -9,905.27 | -3,076.80 | -3,157.08 | |
| EBITDA Coverage | - - | - - | - - | - - | 36,600 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -3.55 | -3.31 | -1.41 | -5.76 | -19.78 | -14.11 | |
|
Price/Earnings (P/E)
|
-2,819.79 | -3,022.89 | -7,097.28 | -1,735.38 | -505.58 | -708.70 | |
| Price/Earnings Growth (PEG) | - - | -51.45 | 360.54 | -6.94 | -11.50 | -3,642.74 | |
|
Price/Book (P/B)
|
-2,593.26 | 513.95 | 563.70 | 711.63 | -243.20 | 367.93 | |
| Price/Tangible Book (P/TB) | -2,593.26 | 513.95 | 563.70 | 711.63 | -243.20 | 367.93 | |
| Price/Sales (P/S) | - - | - - | 8,971.77 | - - | 22,548.99 | 42,298.95 | |
|
Price/Cash Flow (P/CF)
|
-3,415.54 | -3,488.96 | -9,754.65 | -2,350.61 | -857.92 | -1,034.15 | |
| Price/Free CF (P/FCF) | -3,348.82 | -3,440.38 | -9,563.92 | -2,314.13 | -807.00 | -1,000.97 | |
| Price/Operating CF (P/OCF) | -3,415.54 | -3,488.96 | -9,754.65 | -2,350.61 | -857.92 | -1,034.15 |